Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

July 26th 2023

The combination of mRNA-4157 and pembrolizumab will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial.

Fianlimab Plus Cemiplimab Produces Durable Responses in Advanced Melanoma

July 24th 2023

Omid Hamid, MD, discusses the key efficacy and safety findings for the combination of fianlimab plus cemiplimab in patients with advanced melanoma.

Dr Sullivan on the Reduction of ctDNA With Tebentafusp in Metastatic Uveal Melanoma

July 21st 2023

Ryan J. Sullivan, MD, discusses the early reduction of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp and shares how these reductions could correlate with longer overall survival in patients with a best response of stable disease.

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab monotherapy for the adjuvant treatment of patients at least 12 years of age with completely resected stage IIB or IIC melanoma.

Luke Breaks Down Key Clinical Trial Updates From the 2023 ASCO Annual Meeting

July 17th 2023

Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.

DecisionDx-Melanoma 31-Gene Expression Profile Test Stratifies Patients With Cutaneous Melanoma

July 17th 2023

The DecisionDx-Melanoma 31-gene expression profile test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients.

Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C Melanoma

July 12th 2023

Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.

PRT811 Showcases Early Signals of Efficacy in IDH-Mutant Glioma and Uveal Melanoma

July 10th 2023

Varun Monga, MBBS, discusses the mechanism of action of PRT811, key efficacy and safety findings from a phase 1 trial investigating the agent, and potential future directions with this agent in uveal melanoma and IDH-mutant high-grade glioma.

Dr DePalo on First-Line Therapies in Unresectable Melanoma In-Transit Metastases

July 5th 2023

Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.

Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

June 30th 2023

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis–free survival vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Development of FHD-286 Monotherapy Will Not Continue in Metastatic Uveal Melanoma

June 29th 2023

Although the highly potent, selective, allosteric, oral, small molecule BRG1/BRM inhibitor FHD-286 elicited signs of clinical activity and safety as monotherapy in patients with metastatic uveal melanoma in the dose-escalation portion of a phase 1 trial, further development in this indication will not be pursued.

Dr Monga on the Investigation of PRT811 in High-Grade Glioma or Uveal Melanoma

June 26th 2023

Varun Monga, MD, discusses the investigation of the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in patients with recurrent high-grade glioma or uveal melanoma.

Dr Coupe on the Investigation of IMM60 Plus Pembrolizumab in Advanced Melanoma and NSCLC

June 26th 2023

Nicholas Coupe, MBBS, PhD, discusses the investigation of IMM60 plus pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer.

Initial Efficacy and Safety of RP1 + Nivolumab in Patients With Anti–PD-1–Failed Melanoma From the Ongoing Phase 1/2 IGNYTE Study

June 26th 2023

Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.

Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma

June 25th 2023

Camrelizumab combined with famitinib elicited responses and was well tolerated in patients with advanced melanoma previously exposed to an immune checkpoint inhibitor regimen.

Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid Tumors

June 10th 2023

Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.

Nivolumab Plus Relatlimab Demonstrates Consistent Benefit for Patients with Advanced Melanoma

June 7th 2023

Two-year follow-up data from the RELATIVITY-047 trial showed a continued benefit for patients with previously untreated, unresectable, or metastatic melanoma receiving nivolumab plus relatlimab vs nivolumab monotherapy supporting the use of the combination.

Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma

June 7th 2023

The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.

mRNA-4157 Plus Pembrolizumab Improves DMFS in High-Risk Melanoma

June 6th 2023

The combination of mRNA-4157 and pembrolizumab reduced the risk of developing distant metastasis or death by approximately 65% compared with pembrolizumab alone as adjuvant therapy in patients with resected melanoma at high risk of recurrence, according to findings from the phase 2 KEYNOTE-942 trial.

Dr Luke on Results of KEYNOTE-716 of Adjuvant Pembrolizumab in Stage IIB/C Melanoma

June 6th 2023

Jason Luke, MD, FACP, discusses the final analysis of distant metastasis–free survival in the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma.